unstable angina, do not reduce the risk of death (or sudden death) in patients with HF. 8, 9 These observations strongly support the idea that most sudden deaths in patients with HF are arrhythmic rather than ischemic in origin, as has long been suspected.
Ambrosio et al. did report that nebivolol reduced the risk of sudden death, but not the more-definite ischemic composite of death or hospitalization for MI or unstable angina (HR 0.74, 95% CI 0.50-1.09, P = 0.12). 3 This finding could, however, have as much to do with lack of statistical power as with a lack of effect of nebivolol. Clear-cut ischemic events are uncommon in patients with HF. [4] [5] [6] 8, 9 For example, in the MetoprololCR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF), 6 the number of patients who experienced an MI during followup was 35 (1.8%) in the metoprolol CR/XL group and 41 (2.0%) in the placebo group. This result contrasts sharply with the higher numbers of deaths (145 [ Unstable angina is also a notoriously 'soft' end point, meaning that adjudicating with certainty that a patient really had a coronary event is difficult. Characterizing patients with noncoronary chest pain or nonacute coronary pain as having experienced unstable angina introduces 'noise' , which can obscure the effect of treatment on true ischemic events. 10 Owing to the low statistical power of any individual HF trial, owing to the infrequent occurrence of ischemic events in these patients, the answer to the question of whether or not β-blockers reduce such events in patients with HF can only be answered by meta-analysis. Given all we know about β-blockers, such a metaanalysis, if performed, is likely to confirm this effect. Patients, policy-makers, and health-care providers are demanding improvements in comparative effectiveness and safety information. With a wide variety of approved medications for many clinical indications, the relevant question becomes "which is the most effective and safest treatment?", rather than "is the treatment better than placebo?". Randomized controlled trials (RCTs) typically provide the most-valid estimate of treatment efficacy, but have many well-recognized limitations.
1,2
First, all the rele vant treatments are rarely compared with each other; instead, only the active treatment and a placebo, or a limited range of comparators, are assessed. Second, follow-up of patients is typically too short and sample sizes are too small for the true range of treatment toxicities to be to reliably estimated. Finally, participants in RCTs often are not representative of typical patients, limiting the extent to which the benefit and toxicities of the treatment can be generalized outside the narrowly defined study cohort. Meta-analyses of RCTs play an essential role in evidence-based medicine; these studies can strengthen the evidence by combining findings on treatment efficacy, safety, or both across individual RCTs. 3 Most 'traditional' meta-analyses focus on the direct comparisons, such as treatment versus placebo, assigned in the source trials. A network meta-analysis enables the assessment of the relative efficacy and/or safety of treatments by pooling direct and indirect evidence from RCTs. [4] [5] [6] [7] Even in the absence of RCTs comparing two different treatments, a network meta-analysis provides indirect comparison of these treatments by using a common comparator for both agents.
Trelle et al. have compared the cardiovascular safety of several nonsteroidal anti-inflammatory drugs (NSAIDs) using a sophisticated network meta-analysis of 31 RCTs, each with at least 100 patient-years hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF 
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improved so that researchers can answer the questions of both patients and clinicians. Comparisons of at least two active agents are more clinically meaningful than trials involving a placebo, because placebos are not a treatment option in clinical practice. A comparative safety study of analgesics using a large health-care utilization database showed that the therapeutic use of both selective COX-2 inhibitors and opioids was associated with an increased risk of cardiovascular events compared with nonselective COX-2 inhibitors. 9 Comparing the safety of these different analge sics would have been extremely difficult, even with indirect comparison methods, if one could only use clinical trial data. Large health-care utilization databases have been increasingly used as sources of comparative effectiveness or comparative safety research. Although studies in which these databases are used are often limited by the lack of certain clinical information, such as disease severity, they have important strengths, including their size, detailed information on drug exposure, typical patient populations, the capacity to study multiple outcomes of various active treatments for a given condition, easily accessible and inexpensive.
The network meta-analysis by Trelle and colleagues represents a creative and rigorous method for comparative effectiveness, but is limited by the data presented in the original RCTs. Meta-analyses of RCTs and large observational studies each contribute important information and should be considered complementary sources of comparative effectiveness or safety data. of follow-up. 8 Trials of the three most commonly used nonselective NSAIDs (diclofenac, ibuprofen, and naproxen) and four different selective cyclooxygenase-2 (COX-2) inhibitors (celecoxib, etoricoxib, lumiracoxib, and rofecoxib) were included in the analysis. The investigators presented the risk associated of individual NSAIDs by specific cardiovascular outcome, such as myocardial infarction (MI), stroke, cardiovascular death, death from any cause, and the Antiplatelet Trialists' Collaboration composite outcome of nonfatal MI, non fatal stroke, or cardiovascular death (Table 1 ). In terms of cardiovascular outcomes, naproxen was noted to be the safest option as it was the only one of the seven drugs for which the increase in the risk of MI did not exceed 30%. 8 This study largely confirms prior findings that use of all NSAIDs, both nonselective and selective, are associated with an increased risk of cardiovascular adverse events and supported previous regulatory actions. Although the main findings did not take account of dosage, a sensitivity analysis was performed that included only the high-dose trials. This analysis yielded results that were similar to the main findings from the study. The meta-analysis included 116,429 patients with more than 115,000 patient-years of follow-up; however, notably, the risk estimates were imprecise owing to the fairly low number of cardiovascular events associated with individual drugs in the RCTs. Further sensitivity analyses indicated that the investigators' main findings were robust, but most of the reported 95% CIs span the null, limi ting meaningful interpretation of the risks associated with each drug (Table 1) .
One could also question the validity of results from the indirect comparisons of network meta-analyses. These studies are useful tools for comparative effectiveness research in the absence of direct comparisons. However, they are based on many assumptions (for example, homogeneity of treatment effects and consistency of the network), some of which might not hold in all cases. In addition, patient-level data seems not to have been used by Trelle and colleagues, thereby potentially introducing bias if the rate of follow-up differed across treatment arms in the RCTs, which is often the case when an active drug is compared with placebo.
Although cardiovascular risk looms large as a potential risk of nonselective and selective NSAIDs, gastrointestinal toxicity also accounts for substantial morbidity and mortality. When patients and health-care providers discuss the benefits and risks of treatments, aggregate risks are usually considered, rather than focusing on one organ system. As Trelle and colleagues suggest, risks and benefits need to be weighed when making treatment decisions, and composite measures of risks and benefits need to be ''
Comparisons of at least two active agents are more clinically meaningful than trials involving a placebo '' '' Apo A-I has several biological actions that might contribute to its atheroprotective effects '' 
